- cafead Apr 04, 2022 at 11:22: AM
via Novartis CEO Vas Narasimhan is giving the Swiss pharma a huge makeover ahead of a possible spinoff of generics unit Sandoz, pushing out three C-level executives and preparing for layoffs.
Novartis will no longer have oncology and pharmaceuticals as two separate commercial departments. Instead, all Novartis products will merge into one innovative medicines unit to be managed under U.S. and international markets organizations, the company said Monday.
article source
Novartis will no longer have oncology and pharmaceuticals as two separate commercial departments. Instead, all Novartis products will merge into one innovative medicines unit to be managed under U.S. and international markets organizations, the company said Monday.
article source